0      0

JL1109ES - JL1109ES: Efficacy, safety and patient-reported outcomes (PROs) from the Phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence follow

‐ Oct 30, 2023 11:00am

Full author listing

Ann-Lii Cheng, MD, PhD,1 Minshan Chen, MD, PhD,2 Pierce Chow, MBBS, PhD,3 Ahmed Kaseb, MD,4 Han Chu Lee, MD, PhD,5 Adam Yopp, MD,6 Lars Becker, MD,7 Sairy Hernandez, PhD,8 Bruno Kovic, PhD,9 Qinshu Lian, PhD,8 Ning Ma, MD,8 Chun Wu, PharmD,10 Shukui Qin, MD,11 Masatoshi Kudo, MD, PhD12

1National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan, 2Sun Yat-sen University Cancer Center, Guangdong Province, China, 3National Cancer Centre Singapore, Singapore and Duke-NUS Medical School Singapore, Singapore 4MD Anderson Cancer Center, Houston, TX, 5Asan Medical Center, University of Ulsan, Seoul, Republic of Korea; 6UT Southwestern Medical Center, Dallas, TX, 7F. Hoffmann-La Roche, Basel, Switzerland, 8Genentech, Inc., South San Francisco, CA, 9Hoffmann-La Roche Limited, Mississauga, ON, Canada, 10Roche (China) Holding Ltd., Shanghai, China, 11Jinling Hospital of Nanjing University of Chinese Medicine, Nanjing, China, 12Kindai University, Osaka, Japan


You must be logged in and own this session in order to post comments.